左西孟旦治疗老年慢性心力衰竭的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Levosimendan in the treatment of chronic heart failure(CHF)in the elderly.Methods Seventy-two elderly patients with CHF treated in our hospital from February 2017 to February 2019 were selected as the research subjects.The patients were divided into the conventional group and the Levosimendan group according to the random number table method,with 36 patients in each group.In the conventional group,regular treatment was used,and in the Levosimendan group,regular treatment combined with Levosimendan was adopted.The serological indicators,cardiac structure,and clinical treatment effect of the two groups were analyzed.Results After 12 and 24 weeks of treatment,the heart fatty acid binding protein(H-FABP),cardiac troponin I(cTnI),aminoterminal brain natriuretic peptide precursor(NT-proBNP),and endothelium-1(ET-1),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and serum matrix metalloproteinase-9(MMP-9)in the Levosimendan group were lower than those in the conventional group,and the differences were statistically significant(P＜0.05).The nitric oxide(NO),left ventricular ejection fraction(LVEF)and insulin-like growth factor-1(IGF-1)in the levosimendan group were higher than those in the conventional group,the differences were statistically significant(P＜0.05).The total effectiveness rate of treatment in the levosimendan group was higher than that in the conventional group,the difference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Levosimendan can improve the clinical efficacy of CHF in the elderly,which has a good application effect.

Key words： Levosimendan Chronic heart failure Matrix metalloproteinase-9 Insulin-like growth factor-1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Wei-hua
	QIU Wei-lin
	LI Zhi-long

Cite this article:

ZHANG Wei-hua,QIU Wei-lin,LI Zhi-long. Clinical effect of Levosimendan in the treatment of chronic heart failure in the elderly[J]. 中国当代医药, 2020, 27(10): 46-49.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I10/46

[1]	毛承誉，朱华芳，张田田，等.上海市社区中老年人群心力衰竭患病率流行病学调查研究[J].中国预防医学杂志，2019，20（2）：124-127.
[2]	宋芳，李云霞，刘素静.焦作市解放区260 例中老年慢性心力衰竭患者的流行病学特点及影响因素分析[J].齐齐哈尔医学院学报，2019，40（10）：1269-1270.
[3]	郭炜，周红，王肖龙，等.畅心饮治疗老年冠心病慢性心力衰竭的临床研究[J].中西医结合心脑血管病杂志，2019，17（17）：2573-2576.
[4]	李雪霞，张会超.美托洛尔和厄贝沙坦氢氯噻嗪联合治疗老年重症心力衰竭的效果观察[J].中国临床医生杂志，2019，47（9）：1045-1048.
[5]	陈万林，杨平，郑广生，等.顽固性心力衰竭患者应用左西孟旦治疗的效果观察[J].山西医药杂志，2019，48（16）：1993-1994.
[6]	肖大宴.左西孟旦治疗老年扩张型心肌病急性心力衰竭的疗效及对免疫功能的影响[J].中国老年学杂志，2019，39（16）：3873-3875.
[7]	中华医学会心血管病学分会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志，2014，42（2）：98-122.
[8]	郑颖.老年慢性充血性心力衰竭病人的危险因素分析[J].中西医结合心脑血管病杂志，2019，17（7）：1065-1067.
[9]	李琳，莫卿，莫婷，等.老年慢性心力衰竭患者临床特征和药物治疗状况多中心回顾性分析[J].中华医学杂志，2018，98（9）：673-677.
[10]	边圆，王甲莉，程凯，等.2016年欧洲心脏病学会急性心力衰竭指南解读[J].中华急诊医学杂志，2016，25（7）：849-853.
[11]	许顶立，马壮.2018 英国国家卫生与临床优化研究所成年人慢性心力衰竭诊断与管理指南更新解读[J].中国全科医学，2019，22（17）：2015-2019.
[12]	中国中西医结合学会心血管疾病专业委员会，中国医师协会中西医结合医师分会心血管疾病专业委员会.慢性心力衰竭中西医结合诊疗专家共识[J].心脑血管病防治，2016，16（5）：340-347.
[13]	王江友，陈涵，鄢华，等.左西孟旦对猪冠状动脉微栓塞后心肌细胞凋亡的影响[J].中华老年心脑血管病杂志，2018，20（1）：78-82.
[14]	穆立华，张丽华，蒋友旭，等.左西孟旦对LPS 诱导的乳鼠心肌细胞损伤的保护作用[J].郑州大学学报（医学版），2017，52（4）：427-430.
[15]	朱宏旭，宋丽萍，耿学峰.左西孟旦联合多巴胺对顽固性心力衰竭患者心功能及心肌损伤的影响[J].临床和实验医学杂志，2019，18（13）：1404-1407.